Skip to main content

Table 4 Survival of patients

From: An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

 

Median overall survival

 

Time in months (95% CI)

Among the whole cohort (N = 198)

9.8 (8.1-11.4)

Among patients eligible for inclusion in a clinical trial (N = 131)

13.1 (11.2-17.8)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us